More interestingly, re‐introducing WT, but not the enzyme‐inactive variant Nedd4l‐C962A, could inhibit AKT phosphorylation in NEDD4L‐depleted breast cancer cells, coupled with decreased CTR1 protein levels (Figure 5c). The gene discussed is NEDD4L; the disease is breast carcinoma.